Characteristics and outcomes of patients with cancer and chemotherapy associated TMA
| Patient . | Age/ sex . | Type of cancer . | Chemotherapy duration (mo) . | ADAMTS 13 activity (%) . | Platelet count (G/L) . | Hemoglobin (g/dL) . | LDH . | Serum creatinine . | Hematological response . | Renal response . | Serum creatinine at end of follow-up . | Treated with eculizumab (duration) . | Eculizumab continued/ stopped . | Chemotherapy restarted . | Status (duration of follow-up) . | Genetics . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 61/M | Pancreatic | 21 | 87 | 6 | 5.9 | 547 | 2.0 | Y | N | 2.2 | Y/13 mo | Continued | Y | Alive/24 mo | No variants |
| 2 | 73/F | Pancreatic | 12 | 96 | 21 | 7.7 | 742 | 2.5 | Y | Y | 1.4 | Y/13 wk | Stopped | Unknown | Alive/3 mo | No variants |
| 3 | 55/M | SCC of Nasal Cavity | 17 | 56 | 29 | 6.8 | 695 | 4.5 | Y | N | 4 | Y/2 wk | Stopped | N | Deceased/6 mo | No variants |
| 4 | 67/F | Ovarian | 8 | 79 | 199 | 5.9 | 797 | 4.2 | Y | Y | 2.1 | Y/41 mo | Continued | Y | Alive/41 mo | N/A |
| 5 | 53/F | Germ cell tumor | <1 | 42 | 43 | 6.3 | 3459 | 4.8 | Y | Y | 3 | Y/Unknown | Continued | Y | Unknown | No rare pathogenic variant∗ |
| 6 | 54/M | Prostate | N/A | 100 | 11 | 7.4 | 5280 | 13.5 | Y | Y | 1.33 | Y/12 mo | Stopped | Y | Alive/32 mo | No variants |
| 7 | 69/M | DLBCL | N/A | 15 | 17 | 6.5 | 676 | 2.3 | Y | Y | 1.4 | Y/6 wk | Continued | Y | Deceased/65 mo | No variants |
| Patient . | Age/ sex . | Type of cancer . | Chemotherapy duration (mo) . | ADAMTS 13 activity (%) . | Platelet count (G/L) . | Hemoglobin (g/dL) . | LDH . | Serum creatinine . | Hematological response . | Renal response . | Serum creatinine at end of follow-up . | Treated with eculizumab (duration) . | Eculizumab continued/ stopped . | Chemotherapy restarted . | Status (duration of follow-up) . | Genetics . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 61/M | Pancreatic | 21 | 87 | 6 | 5.9 | 547 | 2.0 | Y | N | 2.2 | Y/13 mo | Continued | Y | Alive/24 mo | No variants |
| 2 | 73/F | Pancreatic | 12 | 96 | 21 | 7.7 | 742 | 2.5 | Y | Y | 1.4 | Y/13 wk | Stopped | Unknown | Alive/3 mo | No variants |
| 3 | 55/M | SCC of Nasal Cavity | 17 | 56 | 29 | 6.8 | 695 | 4.5 | Y | N | 4 | Y/2 wk | Stopped | N | Deceased/6 mo | No variants |
| 4 | 67/F | Ovarian | 8 | 79 | 199 | 5.9 | 797 | 4.2 | Y | Y | 2.1 | Y/41 mo | Continued | Y | Alive/41 mo | N/A |
| 5 | 53/F | Germ cell tumor | <1 | 42 | 43 | 6.3 | 3459 | 4.8 | Y | Y | 3 | Y/Unknown | Continued | Y | Unknown | No rare pathogenic variant∗ |
| 6 | 54/M | Prostate | N/A | 100 | 11 | 7.4 | 5280 | 13.5 | Y | Y | 1.33 | Y/12 mo | Stopped | Y | Alive/32 mo | No variants |
| 7 | 69/M | DLBCL | N/A | 15 | 17 | 6.5 | 676 | 2.3 | Y | Y | 1.4 | Y/6 wk | Continued | Y | Deceased/65 mo | No variants |
F, female; M, male; N, no; N/A, not applicable; Y, yes.
Patient 4 had a variant of uncertain significance in CFI (c.1246A>C, p.Ile416Leu, heterozygous) reported on clinical sequencing completed at Cincinnati Children’s Hospital. This was also detected on research sequencing but not considered positive for a rate variant in our analysis because the minor allege frequency was not <0.005 in any ethnic population, our threshold for calling a rare germline variant.